Find-A-Study

Predicting immune checkpoint therapy efficacy of hepatocellular carcinoma

Lay Description

We propose to test whether H1 and H2 clustering can distinguish patients responsive or resistant to the combination therapy with immunotherapy in a prospective clinical study.

Eligibility

Eligible Ages: 18 and over
Eligible Genders: All
Accepts Healthy Volunteers

Inclusion Criteria

1. Patients with HCC who are not candidates for curative or locoregional treatments .

2. Patients who are candidates to receive first-line immunotherapy-based regimens (i.e., atezolizumab/bevacizumab)

3. ECOG performance status 0-2

4. Patients who will have baseline biopsy for HCC and background liver biopsy per SOC

Exclusion Criteria

1. Prior systemic therapy for HCC

2. Any contraindication to immunotherapy

a) Prior transplant

b) Uncontrolled autoimmune diseases (i.e., autoimmune hepatitis)

3. Prior anti-PD-L1, anti-PD1, or anti-CTLA4 antibody (or another checkpoint inhibitor)

Study Design

Arm Groups

Study Contact

Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu

Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu

Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu

Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu

Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu

Jessica Villarreal

villarreal24@uthscsa.edu

Principal Investigator
Sukeshi Arora